🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our fellows Sushmitha Nanja Reddy, Dr. Aditi Sharma and Yating Wang from our affiliate program Ascension Providence MSU Providence Heme Onc displaying their posters and enjoying the last bits of summer in Northern Michigan at the MSHO Annual Meeting 2023 👏🏽👏🏽👏🏽

Karmanos Lung Cancer Symposium: Taofeek K Owonikoko Greg Durm @MeeraRPatel Sonam Puri MD, Antoinette Wozniak. Thought provoking discussion on latest advances in lung cancer treatment. This is arguably the most exciting time to be a thoracic oncologist! Karmanos Cancer Institute #lcam

Not all neoantigens are equivalent!! High clonal neoantigens 👉🏼 better response to immunotherapy. 💡Vigil®, a novel immune technology increases clonal neoantigen targeting immune effector cells, with RFS & OS advantage. Check our recent publication: mdpi.com/2072-6694/15/2…

#ASH23 Dr. Sharma Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute used National Inpt database to determine complications in accquired hemophilia readmission

⭐️What Is a Mentor? | NEJM Having benefited from excellent mentors over the course of her career, a physician author Dr. Suzanne Koven, M.D. concludes that a true mentor is someone who has more imagination about you than you have about yourself. NEJM So true! OncoAlert

Great presentation on Urothelial Cancer by Elisabeth Heath Karmanos Cancer Institute and Khalil Choucair, MD, MSc Karmanos Hematology/Oncology Fellowship at the MSHO Precision Oncology Symposium chaired by Shirish Gadgeel

Tumor mutational burden🧬(TMB) is a regulatory-approved tissue-agnostic predictive biomarker for treatment with immune checkpoint inhibitors . Its adoption in clinical practice is hampered however by technical and biological factors. 1/2

And the champions are Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute

Super proud of our rising stars,🌟✨ Dr. Choucair and Dr. Kamal, for contributing this piece #ASCODailyNews ASCO on the role of IO in EGFR mutant NSCLC #LCSM Khalil Choucair, MD, MSc dailynews.ascopubs.org/do/should-immu…

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Today our study of the association between replication timing alterations and mutation acquisition during cancer evolution has been published in Nature Communications nature.com/articles/s4146…

Please join me for Karmanos Cancer Institute Second Annual Lung Cancer Symposium on Oct. 19 at Detroit Marriott Troy. Online registration is open until 8 a.m., Oct. 18! Visit karmanos.org/lungsymposium to secure your spot. I look forward to seeing you this weekend!

Our work exploring potential biomarkers of IO-therapy in patients of extremes of age, is now published in BMJ Oncology. Anwaar Saeed Karmanos Cancer Institute Caris Life Sciences bmjoncology.bmj.com/content/4/1/e0…

Thank you to everyone who came to the Karmanos Cancer Institute - Dearborn Ribbon Cutting Ceremony yesterday! We are so honored to now be part of this community and bring expert cancer care closer to home. #YourBestChance

Patients over the age of 80 years with cancer treated with immune checkpoint inhibitors can have a favourable response and acceptable toxicity. This is the first study to suggest molecular and immune differences in the ageing process across the three cancer types where ICIs are

linkedin.com/posts/khalilch…